 WATERTOWN, Mass., Aug. 03, 2020 GLOBE NEWSWIRE -- Aileron Therapeutics NASDAQ:ALRN today announced that Manuel Aivado, M.D., Ph.D., President and Chief Executive Officer, will participate in two upcoming investor conferences this month. Thursday, August 6, 2020 Event: William Blair Biotech Focus Conference 2020 Time: 12:00 pm ET Fireside chatThursday, August 13, 2020 Event: Canaccord Genuity 40th Annual Growth Conference Time: 4:30 pm ET Company overview and business update presentationLive webcasts of these events will be available under the Investors and Media section of Ailerons website at A replay of the webcasts will be archived on Ailerons website for 30 days following the respective events.About Aileron TherapeuticsAt Aileron, we are focused on transforming the experience of chemotherapy for cancer patients, enabling them to fight cancer without the fear or burden of chemotherapy-induced side effects. We are advancing ALRN-6924, our first-in-class dual MDM2MDMX inhibitor currently in clinical development, to provide a single medicine to protect multiple healthy cell types throughout the body from chemotherapy while ensuring chemotherapy continues to destroy cancer cells.In addition to potentially reducing or eliminating multiple side effects, ALRN-6924 may also improve patients quality of life and help them better tolerate chemotherapy, potentially allowing patients to complete their treatment without dose reductions or delays. Our long-term vision is to provide chemoprotection for patients with p53-mutated cancers, which represents approximately 50 of cancer patients, regardless of cancer type or chemotherapeutic drug. Visit us at aileronrx.com to learn more. Investor Contacts:Aileron Therapeutics Richard Wanstall, SVP Chief Financial Officer 617-995-0900 C. Vitzthum LifeSci Advisors, LLC. 617-430-7578 Contact: Liz Melone 617-256-6622 